• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

42.24 -0.14 (-0.32%)
Delayed Quote Updated: 9:31 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,411
Open 42.32
Bid (Size) 42.09 (1,700)
Ask (Size) 42.45 (100)
Prev. Close 42.38
Today's Range 42.08 - 42.83
52wk Range 42.36 - 86.74
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗
October 10, 2026
The sell-offs for both of these beaten-down biotech stocks appear to be overdone. 
Via The Motley Fool
News headline image
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗
September 28, 2026
Wall Street expects an even bigger rebound for this beaten-down biotech stock. 
Via The Motley Fool

Performance

52-Week Range 51.3% below 52-week high
42.24
42.3652W Low 86.7452W High
1 Week 7.6% below 1-week high
42.361W Low 45.721W High

Ionis Pharmaceuticals, Inc. - Common Stock (IONS) traded between $42.36 and $86.74 over the past 52 weeks and last traded at $42.24, 51.3% below its 52-week high. Over the past week it ranged between $42.36 and $45.72.

Past 12 Months
-4.3%
-17.9%
-23.1%
-45.0%
-47.0%
-40.2%
1W -$1.91
1M -$9.20
3M -$12.69
6M -$34.52
YTD -$37.43
1Y -$28.35

IONS was -40.2% over the past year, -45.0% over six months, -47.0% year to date, -4.3% in the last week.

12 Months vs Market
IONS
-40.2%
DIA
+11.9%
SPY
+16.9%
QQQ
+22.6%
IWM
+12.1%

Over the past 12 months IONS returned -40.2% versus DIA (Dow) +11.9%, SPY (S&P 500) +16.9%, QQQ (Nasdaq 100) +22.6% and IWM (Russell 2000) +12.1%.

Volume & Liquidity 0.01× 3-mo avg
Today 20,411 3-mo avg 3.4M
1W
3.2M
1M
4.2M
3M
3.4M
6M
2.9M
YTD
2.7M
1Y
2.6M

IONS most recently traded 20,411 shares against a 3-month average daily volume of 3.4M.

More News

Read More
News headline image
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
September 23, 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis Pharmaceuticals (NASDAQ:IONS) Surges After Q2 Earnings Beat Estimates ↗
July 29, 2026
Via Chartmill
Topics Earnings
News headline image
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
September 22, 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook ↗
September 20, 2026
Via The Motley Fool
News headline image
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks ↗
September 19, 2026
Via MarketBeat
News headline image
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗
September 14, 2026
Via The Motley Fool
News headline image
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. ↗
September 09, 2026
Via The Motley Fool
Stay updated with the stocks that are on the move in today's after-hours session. ↗
September 04, 2026
Via Chartmill
News headline image
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
September 04, 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment ↗
September 04, 2026
Via MarketBeat
News headline image
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
September 03, 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present at upcoming investor conferences
September 03, 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗
September 03, 2026
Via The Motley Fool
News headline image
Breakfast News: A Conversation With Ionis CEO ↗
August 22, 2026
Via The Motley Fool
Topics ETFs World Trade
News headline image
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
August 20, 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
August 16, 2026
Via The Motley Fool
News headline image
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? ↗
August 14, 2026
Via The Motley Fool
News headline image
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
August 08, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Ionis (IONS) Q2 2026 Earnings Call Transcript ↗
August 07, 2026
Via The Motley Fool
Topics Earnings
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
August 04, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors? ↗
August 03, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ionis Pharmaceuticals Q2 Earnings Call Highlights ↗
July 29, 2026
Via MarketBeat
Topics Earnings
News headline image
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
July 29, 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?
Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market
What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 42.24
When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 10/14/26 09:31 AM ET
What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 5.99B
How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
Ionis Pharmaceuticals, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap